{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:14:55Z","timestamp":1778858095087,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005298","name":"Universidad de Costa Rica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2020\/10143-7"],"award-info":[{"award-number":["2020\/10143-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2019\/05958-4"],"award-info":[{"award-number":["2019\/05958-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["302643\/2021-4"],"award-info":[{"award-number":["302643\/2021-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["150448\/2022-8"],"award-info":[{"award-number":["150448\/2022-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biochi.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:13:09Z","timestamp":1774249989000},"page":"120-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structural and pharmacological analysis of a PLA2-like toxin in complex with the sPLA2 inhibitor AZD2716: Comparisons to varespladib"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7459-7637","authenticated-orcid":false,"given":"Guilherme H.M.","family":"Salvador","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter L.G.","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-4077","authenticated-orcid":false,"given":"Paula Ladeira","family":"Ortolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo Latorre","family":"Fortes-Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-6469","authenticated-orcid":false,"given":"Bruno","family":"Lomonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-6221","authenticated-orcid":false,"given":"Marcos R.M.","family":"Fontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2026.03.006_bib1","first-page":"L1","article-title":"Envenenamientos por mordeduras de serpientes en Am\u00e9rica Latina y el Caribe: una visi\u00f3n integral de car\u00e1cter regional","author":"Gutierrez","year":"2011","journal-title":"Bolet\u00edn de Malariolog\u00eda Y Salud Ambiental"},{"key":"10.1016\/j.biochi.2026.03.006_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030150","article-title":"Confronting the neglected problem of snake bite envenoming: the need for a global partnership","volume":"3","author":"Gutierrez","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.biochi.2026.03.006_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2023.107024","article-title":"Lys49 myotoxins, secreted phospholipase A2-like proteins of viperid venoms: a comprehensive review","volume":"224","author":"Lomonte","year":"2023","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2026.03.006_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-4800(84)90054-6","article-title":"Pathogenesis of myonecrosis induced by crude venom and a myotoxin of Bothrops asper","volume":"40","author":"Gutierrez","year":"1984","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.biochi.2026.03.006_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109846","article-title":"Synergism between basic Asp49 and Lys49 phospholipase A2 myotoxins of viperid snake venom in vitro and in vivo","volume":"9","author":"Mora-Obando","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2026.03.006_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15614-z","article-title":"PLA2-like proteins myotoxic mechanism: a dynamic model description","volume":"7","author":"Borges","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2026.03.006_bib7","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.bbapap.2014.09.015","article-title":"A structure-based proposal for a comprehensive myotoxic mechanism of phospholipase A2-like proteins from viperid snake venoms","volume":"1844","author":"Fernandes","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biochi.2026.03.006_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73134-9","article-title":"The allosteric activation mechanism of a phospholipase A2-like toxin from Bothrops jararacussu venom: a dynamic description","volume":"10","author":"Gomes","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2026.03.006_bib9","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1107\/S1399004715014443","article-title":"Structural and functional evidence for membrane docking and disruption sites on phospholipase A2-like proteins revealed by complexation with the inhibitor suramin","volume":"71","author":"Salvador","year":"2015","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.biochi.2026.03.006_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/187152811797200669","article-title":"Antivenoms for snakebite envenomings","volume":"10","author":"Gutierrez","year":"2011","journal-title":"Inflamm. Allergy - Drug Targets"},{"key":"10.1016\/j.biochi.2026.03.006_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.toxicon.2018.04.015","article-title":"Toxin-resolved antivenomics-guided assessment of the immunorecognition landscape of antivenoms","volume":"148","author":"Calvete","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2026.03.006_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxicon.2018.11.292","article-title":"Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2","volume":"157","author":"Bryan-Quiros","year":"2019","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2026.03.006_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0041-0101(95)00162-X","article-title":"Neutralization of myonecrosis, hemorrhage, and edema induced by Bothrops asper snake venom by homologous and heterologous pre-existing antibodies in mice","volume":"34","author":"Rucavado","year":"1996","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2026.03.006_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0041-0101(94)90020-5","article-title":"The dynamics of local tissue damage induced by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron microscopic study","volume":"32","author":"Lomonte","year":"1994","journal-title":"Toxicon"},{"key":"10.1016\/j.biochi.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/brain\/awh642","article-title":"Envenoming bites by kraits: the biological basis of treatment-resistant neuromuscular paralysis","volume":"128","author":"Prasarnpun","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.biochi.2026.03.006_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8090248","article-title":"Varespladib (LY315920) appears to be a potent, Broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation","volume":"8","author":"Lewin","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.biochi.2026.03.006_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.biochi.2024.07.016","article-title":"Inhibitors and activators for myotoxic phospholipase A2-like toxins from snake venoms - a structural overview","volume":"227","author":"Salvador","year":"2024","journal-title":"Biochimie"},{"key":"10.1016\/j.biochi.2026.03.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100779","article-title":"Assessing target specificity of the small molecule inhibitor MARIMASTAT to snake venom toxins: a novel application of thermal proteome profiling","volume":"23","author":"Smith","year":"2024","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.biochi.2026.03.006_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/11533650-000000000-00000","volume":"11","year":"2011","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.biochi.2026.03.006_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MOL.0b013e32832dd4c7","article-title":"Phospholipase A2 inhibitors","volume":"20","author":"Garcia-Garcia","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.biochi.2026.03.006_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2010.03.011","article-title":"Phospholipase A2s: developing drug targets for atherosclerosis","volume":"212","author":"Suckling","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biochi.2026.03.006_bib22","first-page":"417","article-title":"A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis","volume":"32","author":"Bradley","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biochi.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/01.CCM.0000171540.54520.69","article-title":"LY315920NA\/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis","volume":"33","author":"Zeiher","year":"2005","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.biochi.2026.03.006_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00000421-199906000-00007","article-title":"Marimastat in patients with advanced pancreatic cancer: a dose-finding study","volume":"22","author":"Rosemurgy","year":"1999","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biochi.2026.03.006_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.129913","article-title":"The synthetic varespladib molecule is a multi-functional inhibitor for PLA2 and PLA2-like ophidic toxins","volume":"1865","author":"Salvador","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biochi.2026.03.006_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53755-5","article-title":"Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound varespladib (LY315920)","volume":"9","author":"Salvador","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2026.03.006_bib27","first-page":"13","article-title":"The search for natural and synthetic inhibitors that would complement antivenoms as therapeutics for snakebite envenoming","author":"Gutierrez","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.biochi.2026.03.006_bib28","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1016\/j.cell.2025.03.050","article-title":"Snake venom protection by a cocktail of varespladib and broadly neutralizing human antibodies","volume":"188","author":"Glanville","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.biochi.2026.03.006_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-015985","article-title":"Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial","volume":"9","author":"Gerardo","year":"2024","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.biochi.2026.03.006_bib30","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acsmedchemlett.6b00188","article-title":"Discovery of AZD2716: a novel secreted phospholipase A2 (sPLA2) inhibitor for the treatment of coronary artery disease","volume":"7","author":"Giordanetto","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biochi.2026.03.006_bib31","doi-asserted-by":"crossref","unstructured":"J.L.S. Hearth, Y, Z. Karjala, N. Casewell, K. Giang, M.R. Lewin, Initial in vitro and in vivo comparisons of AZD2716, its related compounds, varespladib and their preclinical evaluation of snake venom sPLA2 inhibitors,Toxicon X 29 (2026) 100243.","DOI":"10.1016\/j.toxcx.2026.100243"},{"key":"10.1016\/j.biochi.2026.03.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2022.11.006","article-title":"Structural basis of the myotoxic inhibition of the Bothrops pirajai PrTX-I by the synthetic varespladib","volume":"207","author":"Salvador","year":"2023","journal-title":"Biochimie"},{"key":"10.1016\/j.biochi.2026.03.006_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abbi.2000.2244","article-title":"Dissociation of enzymatic and pharmacological properties of piratoxins-I and -III, two myotoxic phospholipases A2 from Bothrops pirajai snake venom","volume":"387","author":"Soares","year":"2001","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biochi.2026.03.006_bib34","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.11609\/JoTT.o4023.6326-34","article-title":"Biology and conservation status of Piraja's lancehead snake Bothrops pirajai Amaral, 1923 (Serpentes: viperidae), Brazil","volume":"6","author":"Freitas","year":"2014","journal-title":"J. Threat. Taxa"},{"key":"10.1016\/j.biochi.2026.03.006_bib35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jep.2007.04.002","article-title":"Neutralization of snake venom phospholipase A2 toxins by aqueous extract of Casearia sylvestris (Flacourtiaceae) in mouse neuromuscular preparation","volume":"112","author":"Cavalcante","year":"2007","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biochi.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.etp.2005.09.004","article-title":"Paralyzing and myotoxic effects of a recombinant bothropstoxin-I (BthTX-I) on mouse neuromuscular preparations","volume":"57","author":"Gallacci","year":"2006","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.biochi.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2015.12.013","article-title":"On the acquisition and analysis of microscale thermophoresis data","volume":"496","author":"Scheuermann","year":"2016","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biochi.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.biochi.2026.03.006_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.biochi.2026.03.006_bib40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.biochi.2026.03.006_bib41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.biochi.2026.03.006_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/pro.3330","article-title":"MolProbity: more and better reference data for improved all-atom structure validation","volume":"27","author":"Williams","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.biochi.2026.03.006_bib43","series-title":"The Pymol Molecular Graphics System","author":"Schrodinger","year":"2010"},{"key":"10.1016\/j.biochi.2026.03.006_bib44","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biochi.2026.03.006_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.biochi.2026.03.006_bib46","doi-asserted-by":"crossref","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"Bussi","year":"2007","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.biochi.2026.03.006_bib47","doi-asserted-by":"crossref","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.biochi.2026.03.006_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00268978400101201","article-title":"A molecular dynamics method for simulations in the canonical ensemble","volume":"52","author":"Nos\u00e9","year":"1983","journal-title":"Mol. Phys."},{"key":"10.1016\/j.biochi.2026.03.006_bib49","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys Rev A Gen Phys"},{"key":"10.1016\/j.biochi.2026.03.006_bib50","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"key":"10.1016\/j.biochi.2026.03.006_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12020131","article-title":"Varespladib (LY315920) and methyl Varespladib (LY333013) abrogate or delay lethality induced by presynaptically acting neurotoxic snake venoms","volume":"12","author":"Gutierrez","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.biochi.2026.03.006_bib54","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s43440-023-00543-8","article-title":"Unraveling snake venom phospholipase A2: an overview of its structure, pharmacology, and inhibitors","volume":"75","author":"Sampat","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biochi.2026.03.006_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238588","article-title":"Inhibitory effects of varespladib, CP471474, and their potential synergistic activity on Bothrops asper and Crotalus durissus cumanensis venoms","volume":"27","author":"Quiroz","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biochi.2026.03.006_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15010062","article-title":"In vitro efficacy of antivenom and varespladib in neutralising Chinese Russell's viper (Daboia siamensis) venom toxicity","volume":"15","author":"Lay","year":"2023","journal-title":"Toxins"},{"key":"10.1016\/j.biochi.2026.03.006_bib57","article-title":"Action of varespladib (LY-315920), a phospholipase A2 inhibitor, on the enzymatic, coagulant and haemorrhagic activities of Lachesis muta rhombeata (South-American bushmaster) venom","volume":"12","author":"Gutierres","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biochi.2026.03.006_bib58","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1038\/s41467-023-43510-w","article-title":"Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms","volume":"14","author":"Hall","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biochi.2026.03.006_bib59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmedchemlett.7b00507","article-title":"Design of selective sPLA2-X inhibitor (-)-2-2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-ylpropanoic acid","volume":"9","author":"Giordanetto","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biochi.2026.03.006_bib52","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41598-018-36839-6","article-title":"Search for efficient inhibitors of myotoxic activity induced by ophidian phospholipase A2-like proteins using functional, structural and bioinformatics approaches","volume":"9","author":"Salvador","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2026.03.006_bib61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jsb.2010.03.019","article-title":"Comparison between Apo and complexed structures of bothropstoxin-I reveals the role of Lys122 and Ca2+-binding loop region for the catalytically inactive Lys49-PLA2s","volume":"171","author":"Fernandes","year":"2010","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.biochi.2026.03.006_bib62","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1016\/S0021-9258(17)39077-4","article-title":"A comparison of the crystal structures of phospholipase A2 from bovine pancreas and Crotalus atrox venom","volume":"260","author":"Renetseder","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biochi.2026.03.006_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbapap.2017.12.008","article-title":"Structural evidence for a fatty acid-independent myotoxic mechanism for a phospholipase A2-like toxin","volume":"1866","author":"Salvador","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biochi.2026.03.006_bib64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/092986609788923310","article-title":"The intriguing phospholipases A2 homologues: relevant structural features on myotoxicity and catalytic inactivity","volume":"16","author":"dos Santos","year":"2009","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.biochi.2026.03.006_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.biochi.2026.03.006_bib65","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/jm060136t","article-title":"The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding","volume":"49","author":"Smart","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biochi.2026.03.006_bib66","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.bmc.2004.01.022","article-title":"Inhibition of the complete set of mammalian secreted phospholipases A2 by indole analogues: a structure-guided study","volume":"12","author":"Smart","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biochi.2026.03.006_bib67","doi-asserted-by":"crossref","first-page":"48535","DOI":"10.1074\/jbc.M205855200","article-title":"Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2","volume":"277","author":"Singer","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biochi.2026.03.006_bib68","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1021\/jm800422v","article-title":"Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2","volume":"51","author":"Oslund","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biochi.2026.03.006_bib69","doi-asserted-by":"crossref","first-page":"13203","DOI":"10.1021\/bi061376d","article-title":"Secreted phospholipase A2 inhibitors are also potent blockers of binding to the M-type receptor","volume":"45","author":"Boilard","year":"2006","journal-title":"Biochemistry"}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908426000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908426000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:34:45Z","timestamp":1778855685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908426000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":68,"alternative-id":["S0300908426000714"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2026.03.006","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and pharmacological analysis of a PLA2-like toxin in complex with the sPLA2 inhibitor AZD2716: Comparisons to varespladib","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. and Soci\u00e9t\u00e9 Fran\u00e7aise de Biochimie et Biologie Mol\u00e9culaire (SFBBM). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}